Swiss National Bank Has $275,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)

Swiss National Bank lowered its stake in Perspective Therapeutics, Inc. (NYSE:CATX) by 6.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 86,260 shares of the company’s stock after selling 5,900 shares during the period. Swiss National Bank owned approximately 0.13% of Perspective Therapeutics worth $275,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Intech Investment Management LLC bought a new position in Perspective Therapeutics during the 3rd quarter worth $137,000. Charles Schwab Investment Management Inc. increased its position in Perspective Therapeutics by 221.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after acquiring an additional 298,778 shares during the period. The Manufacturers Life Insurance Company raised its stake in Perspective Therapeutics by 8.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock worth $274,000 after purchasing an additional 1,672 shares in the last quarter. FMR LLC boosted its holdings in Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after purchasing an additional 5,370,392 shares during the period. Finally, BNP Paribas Financial Markets grew its position in shares of Perspective Therapeutics by 1,302.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock worth $635,000 after purchasing an additional 44,174 shares in the last quarter. 54.66% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CATX has been the subject of a number of analyst reports. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. Scotiabank initiated coverage on Perspective Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Royal Bank of Canada cut their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday, March 19th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $14.44.

Perspective Therapeutics Trading Down 4.3 %

CATX stock opened at $2.20 on Monday. The company has a 50 day simple moving average of $2.94 and a 200 day simple moving average of $6.29. Perspective Therapeutics, Inc. has a 1 year low of $2.19 and a 1 year high of $19.05.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.